Evidence map›Paper›PMID 36803350›Full record

Observational studyBMC cancer2023

An observational study of dose dense chemotherapy with lipegfilgrastim support in early breast cancer.

Ahmed Rashed, Orla M Fitzpatrick, David J Easty, Zac Coyne, Dearbhaile Collins, Victoria Mallet, Maciej Milewski, Keith Egan, Oscar S Breathnach, Liam Grogan and 2 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Ahmed RashedMedical Oncology Department, Beaumont Hospital, Dublin, Ireland.
Orla M FitzpatrickMedical Oncology Department, Beaumont Hospital, Dublin, Ireland. orlafitzpatrick@rcsi.com.
David J EastyMedical Oncology Department, Our Lady of Lourdes Hospital, Drogheda, Co. Louth, Ireland.
Zac CoyneMedical Oncology Department, Beaumont Hospital, Dublin, Ireland.
Dearbhaile CollinsMedical Oncology Department, Beaumont Hospital, Dublin, Ireland.
Victoria MalletCancer Clinical Trials and Research Unit, Beaumont RCSI Cancer Centre, Dublin, Ireland.
Maciej MilewskiCancer Clinical Trials and Research Unit, Beaumont RCSI Cancer Centre, Dublin, Ireland.
Keith EganCancer Clinical Trials and Research Unit, Beaumont RCSI Cancer Centre, Dublin, Ireland.
Oscar S BreathnachMedical Oncology Department, Beaumont Hospital, Dublin, Ireland.
Liam GroganMedical Oncology Department, Beaumont Hospital, Dublin, Ireland.
Bryan T HennessyMedical Oncology Department, Beaumont Hospital, Dublin, Ireland.
Patrick G MorrisMedical Oncology Department, Beaumont Hospital, Dublin, Ireland.
Beaumont Hospital · IEOur Lady of Lourdes Hospital · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBreast cancer is one of the most prevalent malignant diseases in women. The development of dose dense chemotherapy regimens has improved clinical outcomes but has been associated with increased hematological toxicity. Currently there is a paucity of data on the use of lipegfilgrastim in dose dense AC treatment in early breast cancer. The purpose of this study was to assess the use of lipegfilgrastim in the treatment of early breast cancer and to examine the incidence of treatment-related neutropenia during the dose dense AC phase and subsequent paclitaxel treatment.

methodsThis was a single arm, non-interventional, prospective study. The primary endpoint was to determine the rate of neutropenia defined as ANC of < 1.0 × 10

resultsForty-one participants were included in the study. Of the 160 planned dose dense AC treatments, 157 were administered, and 95% (152/160) of these were given on time. The rate of treatment delay was 5% (95% CI 2.2 to 9.9%) due to infection (4) and mucositis (1). Four (10%) patients developed febrile neutropenia. The most frequently occurring adverse event was grade 1 bone pain.

conclusionLipegfilgrastim is an effective option in the prophylaxis of chemotherapy-induced neutropenia, and its use in everyday anti-cancer treatment can be considered.

Indexed as

Breast NeoplasmsFebrile NeutropeniaAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinFemaleFilgrastimGranulocyte Colony-Stimulating FactorHumansPolyethylene GlycolsProspective StudiesCyclophosphamideDoxorubicinFilgrastimGranulocyte Colony-Stimulating FactorpegfilgrastimPolyethylene GlycolsBreast cancerCyclophosphamideDoxorubicinlipegfilgrastimNeutropenia

Identifiers

PMID36803350
PMCPMC9942277
OpenAlexW4321371519

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.